Sabin IPV Vaccine Description
Sabin Inactivated Poliovirus Vaccine (IPV) is a liquid trivalent vaccine produced from Sabin poliovirus type 1, 2, and 3 strains grown on Vero cells.
In 1988, the World Health Assembly adopted a goal of global polio eradication. Since then, polio incidence has decreased by more than 99%, using oral polio vaccine (OPV, Sabin vaccine) and IPV (Salk vaccine) to interrupt transmission.
OPV has the benefits of lower cost compared with IPV and better induction of intestinal/mucosal immunity. It is also associated with vaccine-associated paralytic polio and vaccine-derived poliovirus infections, which have outnumbered wild-type polio infections in recent years.
Sabin IPV Vaccine Indication
This vaccine is indicated to prevent the Wild Polio Virus in the hope of completely eradicating the disease.
Sabin IPV Vaccine Dosage
The vaccine is administered as three intramuscular injections on (0.5ml) Day 0, Day 30, and Day 60, respectively, and a single intramuscular injection of vaccine (0.5 ml) at 18 months.
Sabin IPV Vaccine News
February 19, 2021 - The twenty-seventh WHO meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on the international spread of poliovirus was convened by the WHO Director-General on 1 February 2021 with committee members and advisers attending via video conference, supported by the WHO Secretariat. The Emergency Committee reviewed the data on wild poliovirus (WPV1) and circulating vaccine-derived polioviruses (cVDPV).
January 7, 2021 - South Korean-based biotechnology company announced that its Sabin-Inactivated Polio Vaccine (Sabin-IPV) Eupolio™ is the first to receive the World Health Organization prequalification be supplied globally.
September 1, 2019 - The sIPV is non-inferior compared with IPV. Both demonstrate a good safety profile.
April 8, 2019 - The results of this study were published in The Journal for Infectious Diseases. This analysis revealed that the studied sIPV demonstrated an immunogenicity profile non-inferior to that of the conventional IPV and a good safety profile.
Sabin IPV Vaccine Clinical Trial
Clinical Trial NCT03526978: An Immunogenicity and Safety Phase 3 Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants
The study is a randomized, double-blind, controlled randomized, double-blind, controlled clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) manufactured by Sinovac Vaccine Technology Co., Ltd in 2-month-old infants. The control vaccine is a commercialized Inactivated Poliovirus Vaccine manufactured by Sanofi Pasteur company. 1200 healthy infants between 60-90 days will be randomly assigned into an experimental group or control group in the ratio 1:1.